Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
129 hedge funds and large institutions have $222M invested in Progenics Pharmaceuticals Inc in 2020 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 46 reducing their positions, and 18 closing their positions.
181% more call options, than puts
Call options by funds: $408K | Put options by funds: $145K
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
1% more funds holding
Funds holding: 128 → 129 (+1)
34% less capital invested
Capital invested by funds: $335M → $222M (-$113M)
41% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 46
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$4.74M |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$3.56M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$3.44M |
| 4 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$3.08M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$22.9M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$20.1M |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$3.48M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.98M |
| 5 |
BlackRock
New York
|
-$1.89M |
PGNX Hedge Fund Activity: Q1 2020 in Review
129 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2020, worth a combined $222M — down 34% from $335M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PGNX positions and 18 closed out — a net gain of 5 holders — while 27 added to existing stakes and 46 trimmed.
The largest buyer was Tamarack Advisers, opening a new position worth an estimated $4.74M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $22.9M sold.
- 129 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2020, up from 128 in Q4 2019.
- Funds reported $222M of Progenics Pharmaceuticals Inc stock for Q1 2020, down 34% quarter-over-quarter.
- 23 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2020 and 18 closed out, a net change of +5 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2020 was Tamarack Advisers, an estimated $4.74M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2020 was Eagle Asset Management, an estimated $22.9M sold.
Based on aggregated 13F filings for Q1 2020.